SciELO - Scientific Electronic Library Online

 
vol.29 número2Resistencia a isoniazida y rifampicina en aislados de Mycobacterium tuberculosis en pacientes con coexistencia de tuberculosis y Virus de la Inmunodeficiencia Humana, Colombia 2010 - 2012TriBURTER: invención y validación perceptual del dispositivo portátil de vibración de alta frecuencia y entrenamiento muscular para pacientes con enfermedades respiratorias índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Medicas UIS

versión impresa ISSN 0121-0319

Resumen

OCAMPO-KOHN, Catalina et al. Plasmapheresis in antibody-mediated renal allograft rejection. Experience of Pablo Tobon Uribe, Medellin, Colombia. Year 2005-2015. Medicas UIS [online]. 2016, vol.29, n.2, pp.41-48. ISSN 0121-0319.  https://doi.org/10.18273/revmed.v29n2-2016004.

Background: antibody-mediated renal allograft rejection is a complication after kidney transplantation, and it has poor prognosis for graft survival. Plasmapheresis has been used with controversial results; few trials indicate a trend towards superior graft survival in patients receiving this treatment; however, the evidence remains weak. Objetive: the aim of this study was to describe the experience in treating Antibody-mediated renal allograft rejection with plasmapheresis in kidney transplant recipients. Methods: retrospective and descriptive study of the patients that underwent three to nine session of plasmapheresis as a treatment of severe Antibody-mediated renal allograft rejection in Pablo Tobón Uribe Hospital. Results: between August 2005 and June 2015, 769 patients underwent kidney transplantation at our institution; 26 patients received plasmapheresis as part of the treatment for Antibody-mediated renal allograft rejection. All patients received induction therapy. Maintenance therapy used was tacrolimus, mycophenolic acid and steroids in 80,8% of the patients and cyclosporine, micophenolic acid and steroids in 19,2%. Antibody mediated rejection had an early onset in 61,5% of the cases. At six and 12 months after therapy, 44% and 53,8% patients respectively were back on dialysis. Complications were reported in 53,8% of the patients (hypocalcaemia, hypotension and anaphylaxis). Conclusion: in this cohort, 50% of patients who received Plasmapheresis as therapy for severe Antibody-mediated renal allograft rejection presented loss graft after one year of follow up. It is necessary adding to this therapy new treatment alternatives, among them intravenous immunoglobulin, rituximab, eculizumab and bortezomib. MÉD.UIS. 2016;29(2):41-8.

Palabras clave : Plasmapheresis; Graft rejection; Graft Survival; Kidney transplantation.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons